BUZZ-ADARx Pharmaceuticals to launch Nasdaq IPO with an increased valuation of $446.3 million, expected to open higher
路透社2026/09/25 15:26September 25 - ** Drug developer ADARx Pharmaceuticals (ADRX.O), which is in the late stages of research and development, is expected to see its Nasdaq debut open above its IPO price after increasing the size of its U.S. initial public offering (IPO) to $446.3 million.
** The stock recently indicated an opening price of $23 per share, while the IPO was priced at $17 per share.
** Headquartered in San Diego, ADRX focuses on developing RNA drugs targeting rare diseases. In the upsized IPO, it sold about 26.3 million shares (link). Previously, the company had planned (link) to issue about 21.9 million shares at a price range of $15 to $17 per share.
** In addition, pharmaceutical company AbbVie (ABBV.N) has indicated its intention to subscribe to $100 million worth of shares in a concurrent private placement.
** JPMorgan, Morgan Stanley, TD Cowen, and UBS Investment Bank acted as joint bookrunners for the offering.
(To facilitate non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may be inaccurate or may not capture the required context, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for the convenience of readers. Reuters accepts no liability for any damage or loss caused by the use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analysis: Wall Street Is Not Yet Ready to Short AI in Large Numbers
Overseas capital is aggressively buying US stocks! Net inflows reached $942 billions over the past 12 months, marking a record since 1985.
According to data from the US Department of the Treasury, in the 12 months ending July this year, overseas investors made net purchases of US stocks totaling $942 billion, marking the highest rolling 12-month total since records began in 1985. The net purchases in the second quarter alone reached $426 billion, setting a new single-quarter record. Meanwhile, overseas demand for US Treasuries has noticeably cooled, with purchase volumes falling significantly. As a result, the US is facing higher costs in government debt financing.
RootData: BIO will unlock tokens worth about $1 million in one week
Crypto prices
More
